Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Standard Medicines
Drugs
Locations
Clinical Specialty
961-980 of 1,782 trials

Metastatic Colorectal Cancer: Post-Surgery Chemotherapy Study

We are investigating whether adding chemotherapy after surgery or ablation helps improve outcomes for patients with metastatic colorectal cancer compared to just follow-up care.

Metastatic Colorectal CancerConfirmation phase (III)No PlaceboStandard MedicinesGastroenterologyOncology

Kidney Health: SGLT2 Inhibitor for Prediabetes

We are studying whether adding a new medication to lifestyle changes can help improve kidney function in people with prediabetes. This trial will help us understand its potential benefits for kidney health.

Early Stage Chronic Kidney Disease6-12 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesEndocrinologyNephrology

Fluid Overload in ICU: Furosemide Treatment

We are studying whether a diuretic called furosemide helps critically ill patients with fluid overload recover better than a placebo. The focus is on increasing the number of days alive and out of the hospital after 90 days.

Fluid Overload>2 yearsMonitoring phase (IV)Standard MedicinesPartially RemoteCardiologyInternal MedicinePulmonology

Distal Radius Fracture: Brachial Plexus Nerve Block

We are studying whether an ultrasound-guided nerve block helps adults with distal radius fractures manage pain better than standard treatment during closed reduction. This trial will assess both the benefits and potential risks.

Distal Radius Fracture>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNeurologyOrthopedics and Traumatology

Colorectal Polypectomy: Anticoagulation Study

We are investigating whether continuing blood-thinning medication during polypectomy is safe for patients. The goal is to see if it helps reduce the risk of blood clots during the procedure.

Patients on Anticoagulants for Colonoscopy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesPartially RemoteGastroenterologyHematology

Futibatinib Safety Study for Cancer Patients

We are collecting long-term safety information for patients who previously benefited from futibatinib treatment. This study helps ensure that continuing the medication remains safe for them.

Malignant Solid Tumors1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Small Cell Lung Cancer: Durvalumab Immunotherapy

We are studying whether durvalumab can help frail patients with limited small cell lung cancer live longer without disease progression after receiving thoracic chemoradiotherapy. The trial also examines the treatment's safety and its effects on quality of life.

Limited Stage Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncology

Takayasu Arteritis: Infliximab vs. Tocilizumab

We are studying whether Infliximab is more effective than Tocilizumab for patients with refractory or relapsing Takayasu arteritis. The goal is to see if it helps reduce disease activity and steroid use.

Takayasu's Arteritis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesCardiologyRheumatology

Glibenclamide for High Blood Sugar in Premature Infants

We are studying whether an oral suspension of glibenclamide can help control high blood sugar in premature infants under 1500 grams. The trial will also look at its safety and effects on growth.

Neonatal Hyperglycemia>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesEndocrinologyPediatrics

Cataract Surgery: Preoperative NSAIDs Study

We are comparing how different medication regimens affect inflammation after cataract surgery. This study aims to find the best approach to improve recovery for patients.

Cataract1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesOphthalmology

Multiple Myeloma: SABLe Study with Selinexor

We are investigating a new treatment combination for patients with newly diagnosed multiple myeloma who cannot have a transplant. The study aims to evaluate how well the treatment works and its effects on quality of life.

Multiple Myeloma>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Triple Negative Breast Cancer: Sacituzumab Govitecan and Pembrolizumab Study

We are testing a new treatment combination for patients with triple negative breast cancer who have residual disease after surgery. The study aims to see if this combination improves survival compared to standard treatment options.

Triple Negative Breast Cancer3-6 monthsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteOncology

Multiple Sclerosis: Siponimod Therapy Study

We are exploring how siponimod affects inflammation in patients with active secondary progressive multiple sclerosis. The study aims to understand its impact on disease progression and patient health over time.

Progressive Multiple Sclerosis>2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesNeurology

Major Depressive Disorder: Liposom Forte with Citalopram

We are studying whether Liposom Forte can enhance and speed up the response to citalopram in elderly patients with Major Depressive Disorder. The trial also looks at the safety of this treatment.

Major Depression3-6 monthsMonitoring phase (IV)6-10 visitsStandard MedicinesPsychiatry

Head and Neck Cancer: Carboplatin, Paclitaxel, and Cetuximab Study

We are studying a combination of three medications for patients with recurrent or metastatic head and neck squamous cell carcinoma who did not respond to previous treatments. The goal is to see if this combination improves response rates and overall survival.

Head and Neck Cancer3-6 monthsEfficacy phase (II)No PlaceboStandard MedicinesPartially RemoteOncology

Elderly Primary CNS Lymphoma: High-Dose Chemotherapy Study

We are comparing a high-dose chemotherapy followed by stem cell transplantation to standard chemotherapy for elderly patients with primary CNS lymphoma. The goal is to see which treatment leads to better survival and quality of life.

Primary Central Nervous System Lymphoma (PCNSL)>2 yearsConfirmation phase (III)≤5 visitsNo PlaceboStandard MedicinesHematologyOncology

Amantadine for Improving Alertness in ICU Patients

We are studying whether Amantadine can enhance responsiveness in patients receiving intensive care. The trial will measure changes in alertness over several days using established clinical scoring systems.

Unresponsive Wakefulness Syndrome1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Prostate Cancer: New Radioactive Treatment Study

We are testing a new radioactive drug for adults with metastatic castration-resistant prostate cancer who have not had chemotherapy. The study will assess the safety and how well the treatment works in these patients.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Standard MedicinesOncology

Chemotherapy and Immunotherapy for Pancoast Tumor in Lung Cancer

We are studying the effects of chemotherapy and immunotherapy before and after surgery in patients with non-small cell lung cancer located in the upper part of the lungs. The goal is to see if this approach improves survival and treatment outcomes.

Pancoast's TumorEfficacy phase (II)No PlaceboStandard MedicinesOncology

Small-Cell Lung Cancer: Durvalumab and Olaparib Maintenance Therapy

We are studying the effects of a combination of durvalumab and olaparib for patients with HRD-positive extensive disease small-cell lung cancer after initial treatment. The goal is to see if this maintenance therapy improves outcomes and is safe for patients.

Extensive Stage Small Cell Lung Cancer1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyPulmonology